Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Identifieur interne : 000573 ( Main/Exploration ); précédent : 000572; suivant : 000574Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
Auteurs : Zhijie Wang [République populaire de Chine] ; Jianchun Duan [République populaire de Chine] ; Guoqiang Wang [République populaire de Chine] ; Jing Zhao [République populaire de Chine] ; Jiachen Xu [République populaire de Chine] ; Jiefei Han [République populaire de Chine] ; Zhengyi Zhao [République populaire de Chine] ; Jun Zhao [République populaire de Chine] ; Bo Zhu [République populaire de Chine] ; Minglei Zhuo [République populaire de Chine] ; Jianguo Sun [République populaire de Chine] ; Hua Bai [République populaire de Chine] ; Rui Wan [République populaire de Chine] ; Xin Wang [République populaire de Chine] ; Kailun Fei [République populaire de Chine] ; Shuhang Wang [République populaire de Chine] ; Xiaochen Zhao [République populaire de Chine] ; Yuzi Zhang [République populaire de Chine] ; Mengli Huang [République populaire de Chine] ; Depei Huang [République populaire de Chine] ; Chuang Qi [République populaire de Chine] ; Chan Gao [République populaire de Chine] ; Yuezong Bai [République populaire de Chine] ; Hua Dong [République populaire de Chine] ; Lei Xiong [République populaire de Chine] ; Yanhua Tian [République populaire de Chine] ; Di Wang [République populaire de Chine] ; Chunwei Xu [République populaire de Chine] ; Wenxian Wang [République populaire de Chine] ; Junling Li [République populaire de Chine] ; Xingsheng Hu [République populaire de Chine] ; Shangli Cai [République populaire de Chine] ; Jie Wang [Oman]Source :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2020.
Abstract
INTRODUCTION
Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predict overall survival (OS) benefits, which warrants further exploration.
METHODS
Three independent cohorts of patients with NSCLC treated with immunotherapy were used in this study. A new bTMB algorithm was first developed in the two independent cohorts (POPLAR, N = 211, and OAK, N = 462) and further validated in the third National Cancer Center (NCC) cohort (N = 64).
RESULTS
bTMB-H (bTMB ≥ cutoff point) was not associated with favorable OS after immunotherapy regardless of the cutoff points in either the POPLAR and OAK or the NCC cohorts (p > 0.05) owing to its correlation with the amount of circulating tumor DNA, which was associated with poor OS. In the POPLAR and OAK cohorts, with allele frequency (AF) adjustment, a high AF bTMB (HAF-bTMB, mutation counts with an AF > 5%) was strongly correlated with the amount of circulating tumor DNA (Pearson r = 0.65), whereas a low AF bTMB (LAF-bTMB, mutation counts with an AF ≤ 5%) was not (Pearson r = 0.09). LAF-bTMB-H was associated with favorable OS (hazard ratio [HR] = 0.70, 95% confidence interval [CI]: 0.52-0.95, p = 0.02), progression-free survival (PFS; HR = 0.62, 95% CI: 0.47-0.80, p < 0.001), and objective response rate (ORR) (p < 0.001) after immunotherapy but not chemotherapy, with a cutoff point of 12 trained in the POPLAR cohort and validated in the OAK cohort. The LAF-bTMB algorithm was further validated in the NCC cohort in which LAF-bTMB-H was associated with OS (HR = 0.20, 95% CI: 0.05-0.84, p = 0.02), PFS (HR = 0.30, 95% CI: 0.13-0.70, p = 0.003), and ORR (p = 0.001).
CONCLUSIONS
We developed and validated a new LAF-bTMB algorithm as a feasible predictor of OS, PFS, and ORR after anti-PD-(L)1 therapies in patients with NSCLC, which needs to be prospectively validated.
DOI: 10.1016/j.jtho.2019.12.001
PubMed: 31843683
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.</title><author><name sortKey="Wang, Zhijie" sort="Wang, Zhijie" uniqKey="Wang Z" first="Zhijie" last="Wang">Zhijie Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Duan, Jianchun" sort="Duan, Jianchun" uniqKey="Duan J" first="Jianchun" last="Duan">Jianchun Duan</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Guoqiang" sort="Wang, Guoqiang" uniqKey="Wang G" first="Guoqiang" last="Wang">Guoqiang Wang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Jing" sort="Zhao, Jing" uniqKey="Zhao J" first="Jing" last="Zhao">Jing Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Jiachen" sort="Xu, Jiachen" uniqKey="Xu J" first="Jiachen" last="Xu">Jiachen Xu</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Han, Jiefei" sort="Han, Jiefei" uniqKey="Han J" first="Jiefei" last="Han">Jiefei Han</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhao, Zhengyi" sort="Zhao, Zhengyi" uniqKey="Zhao Z" first="Zhengyi" last="Zhao">Zhengyi Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Jun" sort="Zhao, Jun" uniqKey="Zhao J" first="Jun" last="Zhao">Jun Zhao</name><affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhu, Bo" sort="Zhu, Bo" uniqKey="Zhu B" first="Bo" last="Zhu">Bo Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing</wicri:regionArea><wicri:noRegion>Chongqing</wicri:noRegion></affiliation></author><author><name sortKey="Zhuo, Minglei" sort="Zhuo, Minglei" uniqKey="Zhuo M" first="Minglei" last="Zhuo">Minglei Zhuo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Jianguo" sort="Sun, Jianguo" uniqKey="Sun J" first="Jianguo" last="Sun">Jianguo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing</wicri:regionArea><wicri:noRegion>Chongqing</wicri:noRegion></affiliation></author><author><name sortKey="Bai, Hua" sort="Bai, Hua" uniqKey="Bai H" first="Hua" last="Bai">Hua Bai</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wan, Rui" sort="Wan, Rui" uniqKey="Wan R" first="Rui" last="Wan">Rui Wan</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Xin" sort="Wang, Xin" uniqKey="Wang X" first="Xin" last="Wang">Xin Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Fei, Kailun" sort="Fei, Kailun" uniqKey="Fei K" first="Kailun" last="Fei">Kailun Fei</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Shuhang" sort="Wang, Shuhang" uniqKey="Wang S" first="Shuhang" last="Wang">Shuhang Wang</name><affiliation wicri:level="3"><nlm:affiliation>GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhao, Xiaochen" sort="Zhao, Xiaochen" uniqKey="Zhao X" first="Xiaochen" last="Zhao">Xiaochen Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Yuzi" sort="Zhang, Yuzi" uniqKey="Zhang Y" first="Yuzi" last="Zhang">Yuzi Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Mengli" sort="Huang, Mengli" uniqKey="Huang M" first="Mengli" last="Huang">Mengli Huang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Depei" sort="Huang, Depei" uniqKey="Huang D" first="Depei" last="Huang">Depei Huang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Qi, Chuang" sort="Qi, Chuang" uniqKey="Qi C" first="Chuang" last="Qi">Chuang Qi</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gao, Chan" sort="Gao, Chan" uniqKey="Gao C" first="Chan" last="Gao">Chan Gao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Bai, Yuezong" sort="Bai, Yuezong" uniqKey="Bai Y" first="Yuezong" last="Bai">Yuezong Bai</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Dong, Hua" sort="Dong, Hua" uniqKey="Dong H" first="Hua" last="Dong">Hua Dong</name><affiliation wicri:level="1"><nlm:affiliation>The Bioinformatics Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Bioinformatics Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Xiong, Lei" sort="Xiong, Lei" uniqKey="Xiong L" first="Lei" last="Xiong">Lei Xiong</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Tian, Yanhua" sort="Tian, Yanhua" uniqKey="Tian Y" first="Yanhua" last="Tian">Yanhua Tian</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Di" sort="Wang, Di" uniqKey="Wang D" first="Di" last="Wang">Di Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Xu, Chunwei" sort="Xu, Chunwei" uniqKey="Xu C" first="Chunwei" last="Xu">Chunwei Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian</wicri:regionArea><wicri:noRegion>Fujian</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Wenxian" sort="Wang, Wenxian" uniqKey="Wang W" first="Wenxian" last="Wang">Wenxian Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemotherapy, Zhejiang Cancer Hospital, Zhejiang, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Chemotherapy, Zhejiang Cancer Hospital, Zhejiang</wicri:regionArea><wicri:noRegion>Zhejiang</wicri:noRegion></affiliation></author><author><name sortKey="Li, Junling" sort="Li, Junling" uniqKey="Li J" first="Junling" last="Li">Junling Li</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Hu, Xingsheng" sort="Hu, Xingsheng" uniqKey="Hu X" first="Xingsheng" last="Hu">Xingsheng Hu</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Cai, Shangli" sort="Cai, Shangli" uniqKey="Cai S" first="Shangli" last="Cai">Shangli Cai</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Jie" sort="Wang, Jie" uniqKey="Wang J" first="Jie" last="Wang">Jie Wang</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. Electronic address: zlhuxi@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31843683</idno><idno type="pmid">31843683</idno><idno type="doi">10.1016/j.jtho.2019.12.001</idno><idno type="wicri:Area/Main/Corpus">000559</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000559</idno><idno type="wicri:Area/Main/Curation">000559</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000559</idno><idno type="wicri:Area/Main/Exploration">000559</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.</title><author><name sortKey="Wang, Zhijie" sort="Wang, Zhijie" uniqKey="Wang Z" first="Zhijie" last="Wang">Zhijie Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Duan, Jianchun" sort="Duan, Jianchun" uniqKey="Duan J" first="Jianchun" last="Duan">Jianchun Duan</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Guoqiang" sort="Wang, Guoqiang" uniqKey="Wang G" first="Guoqiang" last="Wang">Guoqiang Wang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Jing" sort="Zhao, Jing" uniqKey="Zhao J" first="Jing" last="Zhao">Jing Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Jiachen" sort="Xu, Jiachen" uniqKey="Xu J" first="Jiachen" last="Xu">Jiachen Xu</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Han, Jiefei" sort="Han, Jiefei" uniqKey="Han J" first="Jiefei" last="Han">Jiefei Han</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhao, Zhengyi" sort="Zhao, Zhengyi" uniqKey="Zhao Z" first="Zhengyi" last="Zhao">Zhengyi Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhao, Jun" sort="Zhao, Jun" uniqKey="Zhao J" first="Jun" last="Zhao">Jun Zhao</name><affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhu, Bo" sort="Zhu, Bo" uniqKey="Zhu B" first="Bo" last="Zhu">Bo Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing</wicri:regionArea><wicri:noRegion>Chongqing</wicri:noRegion></affiliation></author><author><name sortKey="Zhuo, Minglei" sort="Zhuo, Minglei" uniqKey="Zhuo M" first="Minglei" last="Zhuo">Minglei Zhuo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Sun, Jianguo" sort="Sun, Jianguo" uniqKey="Sun J" first="Jianguo" last="Sun">Jianguo Sun</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing</wicri:regionArea><wicri:noRegion>Chongqing</wicri:noRegion></affiliation></author><author><name sortKey="Bai, Hua" sort="Bai, Hua" uniqKey="Bai H" first="Hua" last="Bai">Hua Bai</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wan, Rui" sort="Wan, Rui" uniqKey="Wan R" first="Rui" last="Wan">Rui Wan</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Xin" sort="Wang, Xin" uniqKey="Wang X" first="Xin" last="Wang">Xin Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Fei, Kailun" sort="Fei, Kailun" uniqKey="Fei K" first="Kailun" last="Fei">Kailun Fei</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Shuhang" sort="Wang, Shuhang" uniqKey="Wang S" first="Shuhang" last="Wang">Shuhang Wang</name><affiliation wicri:level="3"><nlm:affiliation>GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Zhao, Xiaochen" sort="Zhao, Xiaochen" uniqKey="Zhao X" first="Xiaochen" last="Zhao">Xiaochen Zhao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Yuzi" sort="Zhang, Yuzi" uniqKey="Zhang Y" first="Yuzi" last="Zhang">Yuzi Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Mengli" sort="Huang, Mengli" uniqKey="Huang M" first="Mengli" last="Huang">Mengli Huang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Depei" sort="Huang, Depei" uniqKey="Huang D" first="Depei" last="Huang">Depei Huang</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Qi, Chuang" sort="Qi, Chuang" uniqKey="Qi C" first="Chuang" last="Qi">Chuang Qi</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Gao, Chan" sort="Gao, Chan" uniqKey="Gao C" first="Chan" last="Gao">Chan Gao</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Bai, Yuezong" sort="Bai, Yuezong" uniqKey="Bai Y" first="Yuezong" last="Bai">Yuezong Bai</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Dong, Hua" sort="Dong, Hua" uniqKey="Dong H" first="Hua" last="Dong">Hua Dong</name><affiliation wicri:level="1"><nlm:affiliation>The Bioinformatics Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Bioinformatics Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Xiong, Lei" sort="Xiong, Lei" uniqKey="Xiong L" first="Lei" last="Xiong">Lei Xiong</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Tian, Yanhua" sort="Tian, Yanhua" uniqKey="Tian Y" first="Yanhua" last="Tian">Yanhua Tian</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Wang, Di" sort="Wang, Di" uniqKey="Wang D" first="Di" last="Wang">Di Wang</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Xu, Chunwei" sort="Xu, Chunwei" uniqKey="Xu C" first="Chunwei" last="Xu">Chunwei Xu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian</wicri:regionArea><wicri:noRegion>Fujian</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Wenxian" sort="Wang, Wenxian" uniqKey="Wang W" first="Wenxian" last="Wang">Wenxian Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemotherapy, Zhejiang Cancer Hospital, Zhejiang, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Chemotherapy, Zhejiang Cancer Hospital, Zhejiang</wicri:regionArea><wicri:noRegion>Zhejiang</wicri:noRegion></affiliation></author><author><name sortKey="Li, Junling" sort="Li, Junling" uniqKey="Li J" first="Junling" last="Li">Junling Li</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Hu, Xingsheng" sort="Hu, Xingsheng" uniqKey="Hu X" first="Xingsheng" last="Hu">Xingsheng Hu</name><affiliation wicri:level="3"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Cai, Shangli" sort="Cai, Shangli" uniqKey="Cai S" first="Shangli" last="Cai">Shangli Cai</name><affiliation wicri:level="1"><nlm:affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>The Medical Department, 3D Medicines, Inc., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Wang, Jie" sort="Wang, Jie" uniqKey="Wang J" first="Jie" last="Wang">Jie Wang</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. Electronic address: zlhuxi@163.com.</nlm:affiliation><country wicri:rule="url">Oman</country></affiliation></author></analytic><series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title><idno type="eISSN">1556-1380</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predict overall survival (OS) benefits, which warrants further exploration.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Three independent cohorts of patients with NSCLC treated with immunotherapy were used in this study. A new bTMB algorithm was first developed in the two independent cohorts (POPLAR, N = 211, and OAK, N = 462) and further validated in the third National Cancer Center (NCC) cohort (N = 64).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>bTMB-H (bTMB ≥ cutoff point) was not associated with favorable OS after immunotherapy regardless of the cutoff points in either the POPLAR and OAK or the NCC cohorts (p > 0.05) owing to its correlation with the amount of circulating tumor DNA, which was associated with poor OS. In the POPLAR and OAK cohorts, with allele frequency (AF) adjustment, a high AF bTMB (HAF-bTMB, mutation counts with an AF > 5%) was strongly correlated with the amount of circulating tumor DNA (Pearson r = 0.65), whereas a low AF bTMB (LAF-bTMB, mutation counts with an AF ≤ 5%) was not (Pearson r = 0.09). LAF-bTMB-H was associated with favorable OS (hazard ratio [HR] = 0.70, 95% confidence interval [CI]: 0.52-0.95, p = 0.02), progression-free survival (PFS; HR = 0.62, 95% CI: 0.47-0.80, p < 0.001), and objective response rate (ORR) (p < 0.001) after immunotherapy but not chemotherapy, with a cutoff point of 12 trained in the POPLAR cohort and validated in the OAK cohort. The LAF-bTMB algorithm was further validated in the NCC cohort in which LAF-bTMB-H was associated with OS (HR = 0.20, 95% CI: 0.05-0.84, p = 0.02), PFS (HR = 0.30, 95% CI: 0.13-0.70, p = 0.003), and ORR (p = 0.001).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>We developed and validated a new LAF-bTMB algorithm as a feasible predictor of OS, PFS, and ORR after anti-PD-(L)1 therapies in patients with NSCLC, which needs to be prospectively validated.</p></div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31843683</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-1380</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>04</Month></PubDate></JournalIssue><Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title><ISOAbbreviation>J Thorac Oncol</ISOAbbreviation></Journal><ArticleTitle>Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.</ArticleTitle><Pagination><MedlinePgn>556-567</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1556-0864(19)33720-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2019.12.001</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predict overall survival (OS) benefits, which warrants further exploration.</AbstractText><AbstractText Label="METHODS">Three independent cohorts of patients with NSCLC treated with immunotherapy were used in this study. A new bTMB algorithm was first developed in the two independent cohorts (POPLAR, N = 211, and OAK, N = 462) and further validated in the third National Cancer Center (NCC) cohort (N = 64).</AbstractText><AbstractText Label="RESULTS">bTMB-H (bTMB ≥ cutoff point) was not associated with favorable OS after immunotherapy regardless of the cutoff points in either the POPLAR and OAK or the NCC cohorts (p > 0.05) owing to its correlation with the amount of circulating tumor DNA, which was associated with poor OS. In the POPLAR and OAK cohorts, with allele frequency (AF) adjustment, a high AF bTMB (HAF-bTMB, mutation counts with an AF > 5%) was strongly correlated with the amount of circulating tumor DNA (Pearson r = 0.65), whereas a low AF bTMB (LAF-bTMB, mutation counts with an AF ≤ 5%) was not (Pearson r = 0.09). LAF-bTMB-H was associated with favorable OS (hazard ratio [HR] = 0.70, 95% confidence interval [CI]: 0.52-0.95, p = 0.02), progression-free survival (PFS; HR = 0.62, 95% CI: 0.47-0.80, p < 0.001), and objective response rate (ORR) (p < 0.001) after immunotherapy but not chemotherapy, with a cutoff point of 12 trained in the POPLAR cohort and validated in the OAK cohort. The LAF-bTMB algorithm was further validated in the NCC cohort in which LAF-bTMB-H was associated with OS (HR = 0.20, 95% CI: 0.05-0.84, p = 0.02), PFS (HR = 0.30, 95% CI: 0.13-0.70, p = 0.003), and ORR (p = 0.001).</AbstractText><AbstractText Label="CONCLUSIONS">We developed and validated a new LAF-bTMB algorithm as a feasible predictor of OS, PFS, and ORR after anti-PD-(L)1 therapies in patients with NSCLC, which needs to be prospectively validated.</AbstractText><CopyrightInformation>Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhijie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Jianchun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guoqiang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiachen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jiefei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhengyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Minglei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jianguo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fei</LastName><ForeName>Kailun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuhang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GCP Center, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xiaochen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuzi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Mengli</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Depei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Chuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Chan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yuezong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Bioinformatics Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yanhua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Chunwei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenxian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Chemotherapy, Zhejiang Cancer Hospital, Zhejiang, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Junling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Xingsheng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Shangli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Medical Department, 3D Medicines, Inc., Shanghai, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China. Electronic address: zlhuxi@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Oncol</MedlineTA><NlmUniqueID>101274235</NlmUniqueID><ISSNLinking>1556-0864</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Oncol. 2020 May;15(5):e69-e72</RefSource><PMID Version="1">32340679</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Oncol. 2020 May;15(5):e72-e73</RefSource><PMID Version="1">32340680</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Allele frequency</Keyword><Keyword MajorTopicYN="Y">Circulating tumor DNA</Keyword><Keyword MajorTopicYN="Y">Immune checkpoint blockade</Keyword><Keyword MajorTopicYN="Y">NSCLC</Keyword><Keyword MajorTopicYN="Y">Tumor mutational burden</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31843683</ArticleId><ArticleId IdType="pii">S1556-0864(19)33720-7</ArticleId><ArticleId IdType="doi">10.1016/j.jtho.2019.12.001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Oman</li><li>République populaire de Chine</li></country><settlement><li>Pékin</li></settlement></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Wang, Zhijie" sort="Wang, Zhijie" uniqKey="Wang Z" first="Zhijie" last="Wang">Zhijie Wang</name></noRegion><name sortKey="Bai, Hua" sort="Bai, Hua" uniqKey="Bai H" first="Hua" last="Bai">Hua Bai</name><name sortKey="Bai, Yuezong" sort="Bai, Yuezong" uniqKey="Bai Y" first="Yuezong" last="Bai">Yuezong Bai</name><name sortKey="Cai, Shangli" sort="Cai, Shangli" uniqKey="Cai S" first="Shangli" last="Cai">Shangli Cai</name><name sortKey="Dong, Hua" sort="Dong, Hua" uniqKey="Dong H" first="Hua" last="Dong">Hua Dong</name><name sortKey="Duan, Jianchun" sort="Duan, Jianchun" uniqKey="Duan J" first="Jianchun" last="Duan">Jianchun Duan</name><name sortKey="Fei, Kailun" sort="Fei, Kailun" uniqKey="Fei K" first="Kailun" last="Fei">Kailun Fei</name><name sortKey="Gao, Chan" sort="Gao, Chan" uniqKey="Gao C" first="Chan" last="Gao">Chan Gao</name><name sortKey="Han, Jiefei" sort="Han, Jiefei" uniqKey="Han J" first="Jiefei" last="Han">Jiefei Han</name><name sortKey="Hu, Xingsheng" sort="Hu, Xingsheng" uniqKey="Hu X" first="Xingsheng" last="Hu">Xingsheng Hu</name><name sortKey="Huang, Depei" sort="Huang, Depei" uniqKey="Huang D" first="Depei" last="Huang">Depei Huang</name><name sortKey="Huang, Mengli" sort="Huang, Mengli" uniqKey="Huang M" first="Mengli" last="Huang">Mengli Huang</name><name sortKey="Li, Junling" sort="Li, Junling" uniqKey="Li J" first="Junling" last="Li">Junling Li</name><name sortKey="Qi, Chuang" sort="Qi, Chuang" uniqKey="Qi C" first="Chuang" last="Qi">Chuang Qi</name><name sortKey="Sun, Jianguo" sort="Sun, Jianguo" uniqKey="Sun J" first="Jianguo" last="Sun">Jianguo Sun</name><name sortKey="Tian, Yanhua" sort="Tian, Yanhua" uniqKey="Tian Y" first="Yanhua" last="Tian">Yanhua Tian</name><name sortKey="Wan, Rui" sort="Wan, Rui" uniqKey="Wan R" first="Rui" last="Wan">Rui Wan</name><name sortKey="Wang, Di" sort="Wang, Di" uniqKey="Wang D" first="Di" last="Wang">Di Wang</name><name sortKey="Wang, Guoqiang" sort="Wang, Guoqiang" uniqKey="Wang G" first="Guoqiang" last="Wang">Guoqiang Wang</name><name sortKey="Wang, Shuhang" sort="Wang, Shuhang" uniqKey="Wang S" first="Shuhang" last="Wang">Shuhang Wang</name><name sortKey="Wang, Wenxian" sort="Wang, Wenxian" uniqKey="Wang W" first="Wenxian" last="Wang">Wenxian Wang</name><name sortKey="Wang, Xin" sort="Wang, Xin" uniqKey="Wang X" first="Xin" last="Wang">Xin Wang</name><name sortKey="Xiong, Lei" sort="Xiong, Lei" uniqKey="Xiong L" first="Lei" last="Xiong">Lei Xiong</name><name sortKey="Xu, Chunwei" sort="Xu, Chunwei" uniqKey="Xu C" first="Chunwei" last="Xu">Chunwei Xu</name><name sortKey="Xu, Jiachen" sort="Xu, Jiachen" uniqKey="Xu J" first="Jiachen" last="Xu">Jiachen Xu</name><name sortKey="Zhang, Yuzi" sort="Zhang, Yuzi" uniqKey="Zhang Y" first="Yuzi" last="Zhang">Yuzi Zhang</name><name sortKey="Zhao, Jing" sort="Zhao, Jing" uniqKey="Zhao J" first="Jing" last="Zhao">Jing Zhao</name><name sortKey="Zhao, Jun" sort="Zhao, Jun" uniqKey="Zhao J" first="Jun" last="Zhao">Jun Zhao</name><name sortKey="Zhao, Xiaochen" sort="Zhao, Xiaochen" uniqKey="Zhao X" first="Xiaochen" last="Zhao">Xiaochen Zhao</name><name sortKey="Zhao, Zhengyi" sort="Zhao, Zhengyi" uniqKey="Zhao Z" first="Zhengyi" last="Zhao">Zhengyi Zhao</name><name sortKey="Zhu, Bo" sort="Zhu, Bo" uniqKey="Zhu B" first="Bo" last="Zhu">Bo Zhu</name><name sortKey="Zhuo, Minglei" sort="Zhuo, Minglei" uniqKey="Zhuo M" first="Minglei" last="Zhuo">Minglei Zhuo</name></country><country name="Oman"><noRegion><name sortKey="Wang, Jie" sort="Wang, Jie" uniqKey="Wang J" first="Jie" last="Wang">Jie Wang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000573 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000573 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31843683
|texte= Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31843683" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |